INTRODUCTION {#SEC1}
============

The chemical composition at the 5′ end of RNAs plays a critical role in all facets of RNA biology, including biosynthesis, processing, transport, and decay ([@B1]). Enzymes that modify or remove these 5′ ends therefore represent key regulatory inputs into these pathways ([@B6]). In eukaryotes, the most common modification that occurs on mRNAs is conversion of the nascent 5′ triphosphate end to a 5′ *N*^7^-methylguanosine (m^7^G) cap ([@B1]). The m^7^G cap is essential for stability, efficient splicing, nuclear export, and translation. In the cytoplasm, the Nudix hydrolase family of decapping enzymes such as Dcp2 and Nudt16 can initiate 5′-3′ mediated decay by hydrolyzing m^7^G caps and releasing m^7^GDP ([@B9]). As a result, these decapping enzymes produce 5′ monophosphate (5′-PO~4~) RNAs for rapid decay by the cytoplasmic processive 5′-3′ exoribonuclease Xrn1 ([@B10],[@B11]).

Our earlier studies show that m^7^G capping does not always proceed to completion and a 5′-end capping quality surveillance mechanism exists in the nucleus to remove the incompletely-capped RNAs. This surveillance pathway is mediated by the DXO/Rai1 family of decapping enzymes ([@B12]), which bears no sequence or structural similarity to the Nudix enzymes. Activity toward incomplete m^7^G caps was first demonstrated with *Schizosaccharomyces pombe* Rai1 (SpRai1), which possesses RNA 5′ pyrophosphohydrolase (PPH) activity (hydrolyzing 5′ triphosphate RNA (pppRNA) to generate pyrophosphate and 5′-PO~4~ RNA) ([@B12]) and non-classical decapping activity (releasing GpppN from unmethylated caps) ([@B13]). Rai1 forms a stable complex with Rat1 (the nuclear homolog of Xrn1) in yeast ([@B16],[@B17]), which also has processive 5′-3′ exoribonuclease activity, thereby coupling decapping with decay. Since then, this decapping activity toward unmethylated caps has been extended to other DXO/Rai1 homologs that have been investigated ([@B18]), including the fungal cytoplasmic Dxo1 ([@B14]) and mammalian DXO ([@B15]).

However, members of the DXO/Rai1 family display distinct activities toward other 5′-end modified RNAs. While mouse DXO has PPH activity, budding yeast Dxo1 cannot hydrolyze pppRNA, and some fungal Rai1 enzymes perform 5′-triphosphonucleotide hydrolase (TPH) activity instead of PPH activity ([@B18]). Additionally, Dxo1 and DXO (and some fungal Rai1 enzymes) possess 5′-3′ exoribonuclease activity toward 5′-PO~4~ RNA and can completely degrade RNA independent of Rat1/Xrn1 exoribonucleases ([@B14],[@B15],[@B18]). Cap surveillance and exonuclease activities can also be reduced by a point modification within the catalytic site, as is the case in *Candida albicans* Rai1 ([@B18]) and *Arabidopsis thaliana* DXO1 ([@B19]).

Structural studies showed that DXO/Rai1 enzymes share a common fold and utilize the same catalytic machinery to perform their various activities ([@B12],[@B14],[@B15],[@B18],[@B20]). Six conserved sequence motifs (I--VI) ([@B18]) form the active site which is located within a deep pocket, and several residues in these motifs bind divalent cations for catalysis. Variable residues within this cavity appear to define their different catalytic activities although it is still not clear in many cases how this takes place ([@B18]).

Recently, the catalog of DXO cellular substrates has expanded to include non-canonical nicotinamide adenine dinucleotide (NAD^+^) capped RNAs ([@B20]). First discovered in bacteria ([@B21]), it was later established that RNAs in yeast and humans can also be modified at their 5′ end by NAD^+^ ([@B20],[@B24],[@B25]). In contrast to prokaryotic NAD^+^ and eukaryotic m^7^G caps that stabilize RNA, eukaryotic NAD^+^ caps promote decay through DXO mediated removal of the entire NAD^+^ moiety (deNADding) ([@B20]). The crystal structures of DXO and Rai1 in complex with the NAD^+^-capped RNA mimic, 3′-phospho NAD^+^ (3′-NADP^+^), demonstrated that the same active site is used to perform the deNADding reaction and that this active site can accommodate the entire NAD^+^ cap ([@B20]).

The recent identification of additional DXO targets engenders the notion that DXO may regulate RNAs with other, less thoroughly studied 5′ ends. While the 5′-PO~4~ group of the substrate is specifically recognized in the active site of DXO for its exonuclease activity ([@B15]), here we demonstrate that DXO surprisingly can also catalyze the hydrolysis of 5′-hydroxyl (5′-OH) RNA. In fact, we show that DXO displays higher activity towards 5′-OH RNA than 5′-PO~4~ RNA. The crystal structure of DXO with a 5′-OH RNA substrate mimic at 2.0 Å resolution illuminates the molecular basis for this activity. More importantly, the structure predicts that DXO initially removes a dinucleotide from 5′-OH RNA, and we have confirmed this 5′-hydroxyl dinucleotide hydrolase (HDH) activity by biochemical studies. Finally, we demonstrate that both SpRai1 and *Arabidopsis* DXO1(ΔN194) have HDH activity, and that the yeast Rat1--Rai1 complex is capable of robust 5′-OH exoribonuclease activity due to removal of the 5′-OH end by Rai1 followed by processive decay by Rat1.

MATERIALS AND METHODS {#SEC2}
=====================

Protein expression and purification {#SEC2-1}
-----------------------------------

Full-length mouse DXO or SpRai1 in pET28a was used to transform *Escherichia coli* BL21 (DE3) Rosetta cells. His-tagged DXO and SpRai1 proteins were produced and purified as previously reported ([@B12]). Briefly, DXO/SpRai1 production was induced with 0.3 mM IPTG at 18°C for 18 h. After cell disruption by sonication and centrifugation, the lysate (in a buffer containing 400 mM NaCl, 20 mM Tris (pH 7.5), 20 mM imidazole, 5 mM β-mercaptoethanol (BME) and 1 mM phenylmethanesulfonylfluoride (PMSF)) was incubated with 2 ml of Ni-NTA superflow resin (Qiagen) with nutation for 1 h. DXO was eluted with 5 ml of buffer containing 250 mM NaCl, 20 mM Tris (pH 7.5), 250 mM imidazole and 5 mM BME and further purified with gel filtration (Sephacryl S-300, GE Healthcare) chromatography (in buffer containing 250 mM NaCl, 20 mM Tris (pH 7.5) and 2 mM DTT). DXO/SpRai1 proteins were supplemented with 5% (v/v) glycerol and concentrated to 10 mg/ml before being frozen in liquid nitrogen.

To produce Rat1 and the Rat1-Rai1 complex, full-length SpRat1 in pET24d (producing Rat1 protein with a C-terminal hexa-histidine tag) and Rai1 in pET26b (producing Rai1 with no affinity tag) were separately used to transform *E. coli* BL21 (DE3) Rosetta cells. After induction with 0.3 mM IPTG and growth at 18°C for 18 h, cells producing Rat1 were lysed and sonicated with or without cells producing Rai1 to generate Rat1 protein alone or Rat1--Rai1 complex respectively ([@B12]). Rat1/Rat1--Rai1 proteins were then purified using the same protocol as that for DXO/SpRai1.

Crystallization, data collection and structure determination {#SEC2-2}
------------------------------------------------------------

DXO crystals were obtained using the hanging-drop vapor diffusion method at 20**°**C with a reservoir solution containing 21--26% (w/v) PEG 3350 ([@B12]). To generate 5′-OH U(S)6 RNA, pU(S)6 RNA was incubated with 5 units of CIP at 37°C for 2 h. Crystals were soaked with 20 mM CaCl~2~ for 1 h followed by soaking in 10 mM 5′-OH U(S)6 (in a fresh drop) for an additional hour at 20**°**C in buffer containing 25% (w/v) PEG 3350. Soaked DXO crystals were cryo-protected with 25% (w/v) PEG 3350 and 25% (v/v) ethylene glycol before being flash frozen in liquid nitrogen for diffraction analysis and data collection at 100 K.

X-ray diffraction data were collected at the Advanced Photon Source (APS) beamline 24-ID-E. The wavelength used was 0.97918 Å. The crystal to detector distance was 250 mm, and each image covered 0.25° rotation of the crystal. The diffraction images were recorded on a Dectris Eiger 16M detector, processed and scaled with standard parameters using the XDS program ([@B26]). Reflections from 800 images were included in the final data set. The crystal was isomorphous to that reported earlier ([@B12]) and belongs to space group *P*2~1~ with 1 molecule in the asymmetric unit. The structure refinement was performed using PHENIX ([@B27]) and manual rebuilding of the atomic model was carried out with the Coot program ([@B28]). Rebuilding of the protein model was completed before the RNA was built into the difference electron density map and included in the refinement. The density for the metal ion was assigned as calcium. It was observed only when the crystal was soaked with this metal ion. The crystallographic information is summarized in Table [1](#tbl1){ref-type="table"}.

###### 

Summary of crystallographic information

  Structure                      DXO in complex with 5′-OH U(S)6 RNA and Ca^2+^
  ------------------------------ ------------------------------------------------
  **Data Collection**            
  Space group                    *P*2~1~
  Cell dimensions                
   *a*, *b*, *c* (Å)             50.2, 87.8, 53.9
   α, β, γ (°)                   90, 112.3, 90
  Resolution (Å)                 49.8--2.0 (2.07--2.0)
  *R* ~merge~ (%)                3.5 (44.7)
  I/σI                           12.3 (2.5)
  Completeness (%)               99.1 (96.7)
  No. of reflections             56459
  Redundancy                     1.9 (1.9)
  **Refinement**                 
  Resolution (Å)                 49.8--2.0 (2.07--2.0)
  *R* ~work~/*R*~free~ (%)       18.9 (33.8) / 22.2 (40.4)
  Number of atoms                3168
   Protein                       2937
   Ligand/Ion                    103
   Water                         128
  *B*-factors (Å^2^)             41.5
   Protein                       40.7
   Ligand/Ion                    60.3
   Water                         45.0
  r.m.s.d.                       
   Bond lengths (Å)              0.005
   Bond angles (°)               0.74
  Ramachandran plot statistics   
   Favored                       97.5
   Allowed                       2.5
   Outliers                      0.0

The average B value for the first two nucleotides of the RNA (51 Å^2^) is higher than that for the protein (41 Å^2^, Table [1](#tbl1){ref-type="table"}). A refinement with the occupancy of this RNA set at 0.8 produced an average B of 43 Å^2^ for these nucleotides. Weak electron density for a nucleotide at the crystal packing interface was observed, and was modeled as 3′-PO~4~ UMP.

Assays with fluorescently labeled RNA {#SEC2-3}
-------------------------------------

A 3′-end FAM-labeled 30-mer G-less RNA ([@B29]), P-ACUCACUCACUCACCAAAAAAAAAAAAACC-FAM, and a 34-mer P-GGGAGACCGGCCUCGAGAUCGAUGAUAUCGAAUU-FAM RNA, with a 5′-monophosphate were treated with CIP for 2 h at 37°C to generate 5′-hydroxyl RNA, confirmed by Xrn1 and Xrn2 exoribonuclease assays. 3′-end FAM-labeled 25-mer RNA oligonucleotides, P-ACUCACUCACUCACCAAAAAAAACC-FAM and OH-ACUCACUCACUCACCAAAAAAAACC-FAM were obtained from Future Synthesis.

Exoribonuclease assays were performed at 37°C for the indicated time periods with reaction mixtures containing 30 mM Tris (pH 8.0) (or pH 6.0--9.0 with appropriate buffers as indicated), 50 mM NH~4~Cl, 2 mM MgCl~2~, 1 mM MnCl~2~, 2 mM DTT, 25 μg ml^−1^ BSA, 100 nM 3′-end FAM-labeled RNA and the indicated amount of recombinant DXO/Rai1 proteins. The products were fractionated by a 7M urea, 16% (w/v) polyacrylamide electrophoresis (PAGE) gel in 1× Tris/Borate/EDTA (TBE) buffer and visualized on a Typhoon FLA 7000 (GE Healthcare).

Assays with radiolabeled RNA {#SEC2-4}
----------------------------

*5′-end hydrolysis assays*. RNA substrate (60 nt: P-AGTCCTCTCTCTCTCCTCTCTCTCCTCTTCCTTCTCTTCCTTCTCCTCTCCTCTTCCTTC) was designed with a T7 ϕ2.5 promoter and a single G nucleotide at the second position to enable the discrimination between mononucleotide and dinucleotide released from the RNA 5′ ends. Radioactively labeled RNA was obtained by *in vitro* transcription with T7 RNA polymerase in the presence of \[α-^32^P\]GTP (Hartmann Analytics) and AMP (Sigma) to generate pRNA that was further treated with alkaline phosphatase FastAP (Thermo Fisher) for 2 h at 37°C to produce OH-RNA. Reactions were carried out in buffer containing 10 mM Tris (pH 7.5), 50 mM KOAc, 2 mM Mg(OAc)~2~, 2 mM MnCl~2~, 1 mM DTT, 0.1 mM spermine, 20 U RiboLock RNase inhibitor, 20 cps of radiolabeled RNA and indicated amount of recombinant protein. Reactions were stopped with 0.05 M EDTA and resolved on polyethyleneimine-cellulose TLC plates in 0.7 M KH~2~PO~4~ (pH 4.5). Plates were analyzed with PhosphorImager Typhoon FLA 9000.

RESULTS {#SEC3}
=======

Mouse DXO displays 5′-3′ exoribonuclease activity on 5′-OH RNA {#SEC3-1}
--------------------------------------------------------------

DXO has distributive 5′-3′ exoribonuclease activity on 5′-PO~4~ RNAs, and this 5′-PO~4~ group is recognized by interactions with Arg132 (conserved motif I) and Gln280 (conserved motif V) ([@B15]). Surprisingly, when we tested the activity of DXO toward 5′-OH RNA substrates, we found that the enzyme is active toward them as well. To compare DXO activity toward 5′-PO~4~ RNA *versus* a 5′-OH RNA, we performed decay assays *in vitro* using a 30 nucleotide G-less RNA with a 3′-FAM (6-carboxyfluorescein) label ([@B29]). As expected, DXO degraded 5′-PO~4~ RNA, generating multiple intermediates, indicative of its distributive activity (Figure [1A](#F1){ref-type="fig"}). DXO also hydrolyzed 5′-OH RNA, and appeared to be faster at removing this 5′-end modification than the subsequent 5′-3′ exonuclease activity toward the 5′-PO~4~ RNA (Figure [1A](#F1){ref-type="fig"}). DXO's preference for 5′-OH substrate and the rate of its hydrolysis were not affected by pH (pH range 6--9), in contrast to the 5′-3′ exonuclease activity, which was more pronounced at higher pH ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}). For both substrates, DXO appeared to be a little slower at removing a 5′ U or A nucleotide than C in the intermediate products, resulting in transient accumulation of intermediates with 5′ U or A. In the case of 5′-PO~4~ and 5′-OH RNA substrates with three consecutive Gs at the 5′ end, the activity toward both was much weaker than that toward the G-less substrate (Figure [1A](#F1){ref-type="fig"}). More importantly, the preference was reversed with a stronger bias toward 5′-PO~4~ RNA than 5′-OH RNA for GGG--RNA (Figure [1B](#F1){ref-type="fig"}). As a control, Xrn1 and Xrn2 were only active toward 5′-PO~4~ RNA (Figure [1C](#F1){ref-type="fig"}), consistent with its dependence on the 5′-PO~4~ modification.

![Mouse DXO displays activity toward 5′-OH RNA. (**A**). Mouse DXO (100 nM) shows activity toward 5′-PO~4~ and 5′-OH G-less FAM-labeled RNA substrates. The 5′-OH substrate (OH-RNA) is degraded faster than the 5′-PO~4~ substrate (P-RNA). The 5′ nucleotide of each RNA product is shown on the right, and those showing transient accumulation are underlined. (**B**). Mouse DXO prefers 5′-OH RNA over 5′-PO~4~ RNA G-less substrates, while the opposite is true for substrates with three Gs at the 5′ end. The 5′-PO~4~ (P-RNA) GGG-RNA is digested more efficiently than the 5′-OH (OH-RNA) GGG-RNA. (**C**). 5′-3′ exoribonuclease activity of 0.003 U Xrn1 or 100 nM Xrn2 on the same 5′-PO~4~ or 5′-OH RNA substrates, demonstrating the absence of activity towards 5′-OH RNA. (**D**). Simultaneous incubation of 400 nM DXO with a 30-mer 5′-PO~4~ RNA and a 25-mer 5′-OH RNA.](gkz1107fig1){#F1}

We confirmed the enhanced activity toward 5′-OH G-less RNA by simultaneously incubating DXO with RNAs containing either a 5′-PO~4~ or a 5′-OH group. In order to more clearly distinguish the products, we used a shorter 5′-OH RNA (25 nucleotides) than 5′-PO~4~ RNA (30 nucleotides). The level of the intact 5′-OH RNA decreased faster than intact 5′-PO~4~ RNA, demonstrating that, depending on the composition, RNA with a 5′-OH can be the preferred substrate for DXO at similar RNA concentrations (Figure [1D](#F1){ref-type="fig"}).

Structural basis for DXO activity toward 5′-OH RNA {#SEC3-2}
--------------------------------------------------

We previously illuminated the mechanism of DXO 5′-3′ exoribonuclease activity toward 5′-PO~4~ RNA releasing single nucleotides ([@B15]). The crystal structures of DXO in complex with the 5′-PO~4~ RNA product pU5, and non-cleavable substrate mimic pU(S)6, (containing two phosphorothioate groups, between the first and second and second and third nucleotides) revealed that the RNA body is accommodated in a positively charged pocket. The active site is located near the bottom of this pocket, where divalent cations bind to position the RNA scissile phosphate (between the first and second nucleotide) for nucleophilic attack.

To understand the molecular basis for the catalytic activity of DXO toward 5′-OH RNA, we determined the crystal structure of wild-type mouse DXO in complex with a 5′-OH hexa-nucleotide non-hydrolyzable RNA substrate mimic, OH-U(S)6. OH-U(S)6 was generated by incubating pU(S)6 with calf intestinal alkaline phosphatase (CIP) to remove the 5′-PO~4~ group. As we demonstrated with another RNA, 5′-PO~4~ RNA treated in this way was successfully degraded by DXO but not by Xrn2 (Figure [1C](#F1){ref-type="fig"}), confirming the removal of the 5′-PO~4~ group. DXO crystals were soaked with OH-U(S)6 RNA and with calcium as the divalent cation to further block hydrolysis. The structure was determined at 2.0 Å resolution and has excellent agreement with the X-ray diffraction data and the expected bond lengths, bond angles and other geometric parameters (Table [1](#tbl1){ref-type="table"}).

We observed good electron density for four nucleotides of the OH-U(S)6 RNA (Figure [2A](#F2){ref-type="fig"}) and a calcium ion in the complex with DXO (Figures [2B](#F2){ref-type="fig"}, [C](#F2){ref-type="fig"}). An additional nucleotide at the 3′ end showed weak electron density and was not modeled. The 5′-end nucleotide contains a hydroxyl moiety, again confirming the removal of the 5′-PO~4~ group during the CIP treatment (Figure [2A](#F2){ref-type="fig"}). We were able to unambiguously assign the nucleotide positions due to the stronger electron density of sulfur atoms in the phosphorothioate groups compared to oxygen (Figure [2A](#F2){ref-type="fig"}), which also confirmed that there was no hydrolysis of this RNA during crystallization. The average *B* value for the first two nucleotides of the RNA is 51 Å^2^, higher than that for the protein (41 Å^2^, Table [1](#tbl1){ref-type="table"}), suggesting that the RNA may be at a somewhat lower occupancy (∼80%) in the crystal. Nonetheless, the observed electron density for the RNA (Figure [2A](#F2){ref-type="fig"}) provides clear indication of its binding mode.

![Crystal structure of mouse DXO in complex with 5′-OH-U(S)6. (**A**) Simulated annealing omit *F*~o~ -- *F*~c~ electron density at 2.0 Å resolution for 5′-OH U(S)6 RNA, contoured at 2σ. (**B**) Overall structure of mouse DXO (cyan) in complex with 5′-OH-U(S)6 RNA (in black for carbon atoms). (**C**) Overall structure of mouse DXO (cyan) in complex with 5′-OH-U(S)6 RNA, viewed after 90° rotation around the vertical axis. (**D**) Overlay of the active site region of mouse DXO in complex with 5′-OH U(S)6 RNA (in color) with that in complex with pU(S)6 RNA (gray; PDB: 4J7M) ([@B15]). The calcium ion from the pU(S)6 structure is shown in orange.](gkz1107fig2){#F2}

There is electron density for a calcium ion bound to the active site residues (Asp236, Glu253 and Glu192) (Figure [2D](#F2){ref-type="fig"}), and this density is not observed in crystals not soaked with calcium. However, the calcium ion contacts the phosphorothioate group between the second and third nucleotides of this RNA instead of between the first and second as was observed with pU(S)6 ([@B15]) (Figure [2D](#F2){ref-type="fig"}). This suggests that the scissile phosphate of this 5′-OH RNA is located between its second and third nucleotides, and more importantly, it predicts that DXO generates a 5′-OH dinucleotide as the first product of the hydrolysis. To be consistent with the earlier nomenclature in terms of the nucleotides in the RNA substrate ([@B15]), we named the four observed nucleotides in the OH-U(S)6 RNA U~0~, U(S)~1~, U(S)~2~, and U~3~, so that the scissile phosphate is located between U~1~ and U~2~ (Figures [2A](#F2){ref-type="fig"}, [D](#F2){ref-type="fig"}).

The U~0~ base has π stacking interactions with the mostly conserved Trp131 side chain, and it also makes three hydrogen-bonding contacts: to the backbone carbonyl of Arg102 and the side chain of His105 directly and to the backbone amide of His105 through a water molecule (Figure [2D](#F2){ref-type="fig"}). The 5′-OH moiety itself is intimately packed against the base of U(S)~1~ (Figure [2D](#F2){ref-type="fig"}). The presence of a phosphate here would make it impossible to adopt this conformation, which may account for why 5′-PO~4~ RNA cannot bind in this manner.

The overall structure of DXO in the OH-U(S)6 complex is essentially the same as that of the pU(S)6 complex, with rms distance of 0.3 Å for 358 equivalent Cα atoms between the two structures. The conformation of most of the side chains in the active site region is similar between the two structures as well (Figure [2D](#F2){ref-type="fig"}). However, there are substantial differences in the binding modes of the U(S)~1~ nucleotide between OH-U(S)6 and pU(S)6 (Figure [2D](#F2){ref-type="fig"}). The position of its 5′ phosphate group of OH-U(S)6 differ by 1.5 Å compared to that of pU(S)6, although the two phosphates can maintain similar interactions with DXO. The U(S)~1~ base moves by ∼3 Å, and the position of the U(S)~1~ base in the pU(S)6 structure would clash with the 5′-OH of the OH-U(S)6 RNA (Figure [2D](#F2){ref-type="fig"}). In addition, the U(S)~1~ base is in the *syn* configuration in OH-U(S)6 RNA, while it is *anti* in pU(S)6. In comparison, the conformation of the U~2~ and U~3~ nucleotides in OH-U(S)6 RNA is nearly the same as that in pU(S)6.

The U~0~ nucleotide is accommodated deeper within the DXO active site (Figure [3A](#F3){ref-type="fig"}) and is in the same general region as the nicotinamide diphosphate moiety of the NAD^+^ cap and GDP (Figures. [3B](#F3){ref-type="fig"}--[D](#F3){ref-type="fig"}) ([@B12],[@B15],[@B20]). Most of the DXO side chains in these structures are in the same conformation except for Arg95. Arg95 interacts with the ribose hydroxyls and makes van der Waals contacts with the adenine base in the 3′-NADP complex (Figure [3C](#F3){ref-type="fig"}) and with the guanine base in the GDP complex (Figure [3D](#F3){ref-type="fig"}), but it swings out of the way with 5′-OH RNA where it only hydrogen bonds with the U~1~ base. Together these structures demonstrate that DXO can carry out multiple catalytic activities by being able to accommodate and make specific contacts to various orientations of the 5′ modification.

![Comparison of 5′-OH U(S)6 RNA binding mode to other DXO ligands. (**A**) The active site pocket. Surface representation of mouse DXO in the active site region, colored by the electrostatic potential (with blue and red indicating positive and negative potential, respectively). Two helices near the opening of the pocket are shown as cartoons for clearer visualization of the pocket. (**B**) Overlay of the active site region of mouse DXO in complex with 5′-OH U(S)6 RNA (in color) with that in complex with pU5 RNA (gray; PDB: 4J7L) ([@B15]). The 2 magnesium ions in the pU5 complex are shown in pink. (**C**) Same as in B but with the 3′-NADP complex (PDB: 5ULI) ([@B20]). (**D**) Same as in B but with the GDP complex (PDB: 3FQJ) ([@B12]).](gkz1107fig3){#F3}

DXO releases a 5′-dinucleotide from 5′-OH RNA {#SEC3-3}
---------------------------------------------

We next set out to confirm our structural prediction that DXO releases a dinucleotide from 5′-OH RNA as the first product. We performed exoribonuclease assays and monitored the initial cleavage events. 3′-end 6-FAM labeled RNA with either a 5′-PO~4~ or 5′-OH was incubated with DXO, and the products were separated on a denaturing gel that could clearly resolve single nucleotide changes to the RNA. The first RNA product released from 5′-OH RNA migrated at the same position as the second product released from 5′-PO~4~ RNA, suggesting that DXO released a dinucleotide from 5′-OH RNA in the first step of the reaction (Figure [4A](#F4){ref-type="fig"}). We propose the name 5′-hydroxyl dinucleotide hydrolase (HDH) for this activity. After the initial dinucleotide cleavage from 5′-OH RNA, single nucleotides were released thereafter, signifying that the remaining RNA has a 5′-PO~4~.

![DXO releases a 5′-dinucleotide from 5′-OH RNA. (**A**) Time course monitoring early points of the 5′-3′ exoribonuclease reaction with 10 nM DXO and G-less 5′-PO~4~ RNA (P-RNA) and OH-RNA. (**B**) Product formation after incubation for 1 min of G-less P-RNA and OH-RNA with increasing concentrations of DXO. (**C**) TLC of the exoribonuclease reaction after 30 min using 10 nM mouse DXO with RNAs radiolabeled on the phosphate between the first and second nucleotides. The migration of the 5′ nucleotides are indicated. (**D**) Same as C but a time course using 5 nM mouse DXO.](gkz1107fig4){#F4}

To further confirm that DXO releases a 5′-OH dinucleotide leaving behind a 5′-PO~4~ RNA, we used an RNA radiolabeled on the phosphate between the first and second nucleotide, and carried out TLC (thin layer chromatography) to separate the reaction products. Consistent with our crystal structure and gel based assays, DXO released a 5′-OH dinucleotide from 5′-OH RNA but single nucleotides from 5′-PO~4~ RNA (Figures [4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}).

DXO homologs also have HDH activity {#SEC3-4}
-----------------------------------

Similar to DXO, SpRai1 has PPH, decapping and deNADding activities, but lacks 5′-PO~4~ 5′-3′ exoribonuclease activity ([@B12],[@B13],[@B20]). To assess whether SpRai1 also has HDH activity, we compared the decay of 5′-PO~4~ and 5′-OH RNAs by Rai1 and the Rat1--Rai1 complex *in vitro*. Unlike DXO, SpRai1 did not display any activity toward 5′-PO~4~ RNA under the condition tested but could perform a single cleavage reaction on 5′-OH RNA with no further decay of the resultant RNA ( Figure [5A](#F5){ref-type="fig"}), confirming that it has HDH activity. On the other hand, Rat1 alone displayed processive activity toward 5′-PO~4~ but showed no activity toward 5′-OH RNA (Figure [5B](#F5){ref-type="fig"}). Consistent with previous studies, this activity was enhanced in the presence of Rai1 (Figure [5C](#F5){ref-type="fig"}). Interestingly, the Rat1-Rai1 complex also showed robust activity toward 5′-OH RNA (Figure [5C](#F5){ref-type="fig"}), while Rat1--Rai1 with the catalytically inactive Rat1 mutant E205Q displayed the same activity as Rai1 alone (Figure [5D](#F5){ref-type="fig"}). These data demonstrate that in the context of the Rat1--Rai1 complex, Rai1 only processes the terminal nucleotide(s) of 5′-OH RNA, while Rat1 is responsible for decay of 5′-PO~4~ RNA.

![DXO homologs also have HDH activity. (**A**) Time course of the 5′-3′ exoribonuclease activity of 5 nM wild-type (WT) *S. pombe* Rai1 toward 5′-PO~4~ or 5′-OH RNA. (**B**) Same as A but with WT *S. pombe* Rat1 alone. (**C**) Same as in A but with wild-type Rat1-Rai1 complex. (**D**) Same as in A but with a complex of WT Rai1 and catalytic inactive Rat1 (E207Q). (**E**) Simultaneous incubation of 400 nM mouse DXO or *Arabidopsis* DXO1(ΔN194) with 30-mer 5′-PO~4~ RNA and a 25-mer 5′-OH RNA.](gkz1107fig5){#F5}

We also found that the *Arabidopsis* homolog AtDXO1 is active toward the 5′-OH RNA substrate. We showed earlier that the DXO1(ΔN194) variant, which lacks the N-terminal 194 plant-specific amino acids, has PPH activity ([@B19]). We tested this variant against a mixture of two RNA substrates containing 5′-PO~4~ or 5′-OH. DXO1(ΔN194) was also able to hydrolyze 5′-OH RNA, but, in contrast to mouse DXO, it had a reduced activity toward this substrate and showed a preference for 5′-PO~4~ RNA (Figure [5E](#F5){ref-type="fig"}).

DISCUSSION {#SEC4}
==========

DXO has previously been shown to possess PPH, decapping, and deNADding activities, and it is unique among the decapping enzymes as it can also completely degrade RNA using its 5′-PO~4~-dependent, distributive 5′-3′ exoribonuclease activity ([@B12],[@B15],[@B20]). Here we report an additional activity for the DXO/Rai1 family of enzymes, which is catalyzing the hydrolysis of 5′-OH RNA. DXO initially removes a dinucleotide from 5′-OH RNA, and we propose the name 5′-hydroxyl dinucleotide hydrolase (HDH) for this novel activity. These observations buttress the idea of DXO as a multi-purpose eraser of RNA 5′-end modifications. On the other hand, these distinct activities all share the same catalytic machinery and generate 5′-PO~4~ RNA (pRNA) as a common product (Figure [6](#F6){ref-type="fig"}), which can be further degraded by DXO and Xrn1/Xrn2. At the same time, DXO does display some 5′-end specificity (at least with respect to decapping and exoribonuclease activities), as RNAs with a 2′-*O*-methyl cap (cap1 and cap2) cannot be degraded ([@B30]).

![The diverse catalytic activity of DXO/Rai1 enzymes. The various catalytic activities of the DXO/Rai1 family enzymes are shown. They use the same catalytic machinery and share a common product, 5′-PO~4~ RNA (pRNA). Additional activities toward other 5′-end modified RNAs are possible as well, indicated by the question marks.](gkz1107fig6){#F6}

5′-OH RNA is known to exist in eukaryotes, resulting from the activity of some endoribonucleases, self-cleaving ribozymes and intramolecular phosphodiester cleavage ([@B31]). 5′-OH RNA are intermediates in critical pathways such as ribosomal and transfer RNA processing, and in quality control pathways such as No-Go decay (NGD) ([@B37]). It has been thought that the decay of some of these 5′-OH RNAs involves phosphorylation by RNA kinases to produce 5′-PO~4~ RNAs, although it is not known if this mechanism applies to all such RNAs. Our studies suggest that DXO and Rat1-Rai1 may also be involved in the removal of such 5′-OH RNAs in cells. In fact an active-site mutant of the cytoplasmic Dxo1 in yeast stabilizes a 5′-OH RNA intermediate in the NGD pathway ([@B39]), and Rai1 has some Rat1-independent RNA processing activities which could be related to its HDH activity ([@B40]). Notably, 5\'-OH cleavage products from pre-rRNA may also be further processed by Rai1 HDH activity, since endonuclease Las1 responsible for this cleavage has been reported to act in a complex with Rai1 ([@B39]). Previously, only Rrp17 (Nol12 in humans), which is involved in rRNA processing, was shown to have 5′-OH RNA exoribonuclease activity in eukaryotes ([@B41]). Together, our studies have uncovered an additional route for 5′-3′ eukaryotic RNA decay.

An interesting question arises as to the fate of the 5′-OH dinucleotide that is released by DXO from 5′-OH RNA. Dinucleotide nucleases, for example Orn in bacteria ([@B42]) and Rexo2 in humans ([@B43]), can degrade such oligos in a 3′-5′ direction. Therefore, it would be interesting to find out if Rexo2 and related enzymes could mediate the degradation of the 5′-OH dinucleotide product from DXO.

Our crystal structure of DXO with 5′-OH RNA provides the molecular basis for the HDH activity, and it may also explain why this activity can be higher than that toward 5′-PO~4~ RNA. By accommodating an additional nucleotide 5′ to the scissile phosphate compared to 5′-PO~4~ RNA, DXO can make further contacts to 5′-OH RNA, mainly through a stacking interaction of the terminal base with the highly conserved Trp131 residue. The *syn* configuration of the next base may also increase binding of DXO to 5′-OH RNA since the conserved Tyr189 can then pack between U~1~ and U~2~ in this conformation. Finally, the 5′-OH group is positioned against the U~1~ base thus discriminating against a terminal 5′-PO4.

DXO activity toward 5′-OH RNA was previously tested but the enzyme was found to be inactive ([@B15]). This discrepancy may be due to differences in the RNA sequences used for our structural and biochemical analyses *versus* previous studies (uracil and adenosine versus guanosine). Our assays here indicate that activity toward 5′-OH RNA appears to be strongly sequence-dependent and in substrates lacking G at their 5′ ends the 5′-OH RNA is preferentially digested in comparison to the 5′-PO~4~ RNA. The decreased activity toward RNA with 5′ Gs may explain why DXO was previously reported to be inactive toward 5′-OH RNA ([@B15]). On the other hand, U and C are hydrolyzed faster than A suggesting that DXO is more active toward pyrimidines than purines at the 5′ end. The exact mechanism for this sequence preference by DXO will require further structural and biochemical studies to illuminate. It might be possible that a 5′-OH GG dinucleotide is docked into the active site in a less optimal conformation than a 5′-PO~4~ GG dinucleotide.

We demonstrate that SpRai1 and AtDXO1 can also degrade 5′-OH RNA, thereby extending the HDH activity to other DXO homologs. Similar to DXO, SpRai1 has a strong preference for 5′-OH RNA, although AtDXO1 prefers 5′-PO~4~ RNA. The differing activities of DXO homologs toward these RNAs further demonstrate the diversity of activities within the DXO/Rai1 enzyme family and suggest that the extent of degradation of 5′-OH RNAs *in vivo* may vary depending on the organism. At least in *S. pombe*, the HDH activity of SpRai1 licenses the Rat1--Rai1 complex the ability to completely degrade 5′-OH RNA, which is a novel activity for Rat1--Rai1 and could lead to uncovering new functions for this complex.
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